Navigation Links
Houston Fertility Institute Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures
Date:9/26/2013

cally designed and developed for use following in vitro fertilization (IVF) procedures to improve pregnancy success rates and outcomes. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100's mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information about Nora Therapeutics, visit www.noratherapeutics.com.

 

 

 


'/>"/>
SOURCE Nora Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. University of Houston launches first nanotech company
2. DTx to Introduce Data Acquisition Control & Robotic Instrument (DACRI) at Clinical Lab Expo in Houston, TX.
3. Cato Research and Cato BioVentures Announces the Opening of Houston, Texas, Office
4. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
5. Merck Company Foundation Announces HIV Care Collaborative with Atlanta, Houston and Philadelphia Health Departments
6. Specialty Chemical Forum 2012 Kicks Off in Houston; AkzoNobels Frank Sherman Delivers Keynote Address
7. WellnessFX Launches New Products e-HealthAnswers and Womens Fertility Package
8. Decorated, Retired Colonel Leads Fertility Care at TFC-Round Rock
9. Vaginal Ring Provides “Radically New” Drug Delivery Platform for Health Issues, Including Infertility
10. 12,000 Candles: Texas Fertility Center 27th Annual Baby Reunion, Celebrates 12,000 Babies Born
11. Texas Fertility Center Introduces Oncofertility Education Program for Physicians and Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Working in collaboration with the National ... London , Richmond Pharmacology is the first centre worldwide ... for an investigational RNAi therapeutic being developed for the treatment ... and heart. Read press release ... at St Georges University of London , ...
(Date:3/27/2015)... 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... focus on China , today reported ... December 31, 2014.  The Company reported ... share, for the three months ended December 31, 2014.  ...
(Date:3/26/2015)... March 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... on providing advanced testing solutions for the detection ... for the three months and full year ended ... Financial Results:Revenue for the quarter ended December 31, ... the fourth quarter of 2013 and $1.5 million ...
(Date:3/26/2015)... 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... dealing with certain matters, including the appointment of auditors, ... March 26, 2015 (the "Meeting") was adjourned, as previously ... at 11:00 a.m. ( Toronto time). ... from that previous disclosed. The Meeting will reconvene at ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... Drives Physician Prescribing of Copaxone over an Interferon-Beta Therapy, According ... ... Resources, WALTHAM, Mass., March 11 Decision ... pharmaceutical and,healthcare issues, finds that Teva Pharmaceutical,s Copaxone has the,greatest patient ...
... Biosystems,( http://www.altogen.com ) announced launch of new ... Altogen Custom Services focus on,providing specialized biotechnology ... generation of stably-expressing cell,lines, assay development, screening ... draw upon their unique experience with over,hundred ...
... -Advances Reported in All Three Clinical Programs, Including Launch of ... Bavituximab Phase ... Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... (HCV) infection, today announced financial results for,the third quarter of ...
Cached Biology Technology:Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 10
(Date:3/5/2015)... , March 5, 2015 In Brazil ... of companies already using these solutions and 42 percent planning ... the latter, approximately 25 percent of the companies will be ... While the majority of companies in the region are currently ... the hybrid model will command significant attention in the coming ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
(Date:3/2/2015)... March 2, 2015  Businesses have a new ... company Tharon Rankins Enterprises has announced the launch ... ultra-safe way for businesses to protect their customers, ... Beconux is a biometric transaction ... Functioning similarly to an ATM machine, the new ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2
... GAINESVILLE, Fla. The wild pea pod is big and ... its parent plant. And yet, like a grounded teenager ... if it has a reasonable chance of escape. ... landscape devoted to wildlife corridors greenways that link woods ...
... Scientists from Scripps Institution of Oceanography at UC ... have captured unprecedented details of vibrant sea life ... documentations of new species and marine animals previously ... surveys at unexplored depths, have revealed disturbing declines ...
... the United States continues to develop alternative energy methods ... as one of the most commercially viable technologies. Corn ... loss of soil organic carbon (SOC) associated with the ... is of agricultural and environmental concern. ...
Cached Biology News:Rooted plants move mysteriously down greenways, scientists say 2Rooted plants move mysteriously down greenways, scientists say 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 2Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 4Managing carbon loss 2
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... The Infinite 200 series of microplate ... or absorbance detection in an affordable, easy-to-use ... science applications. The unique modular design and ... researchers with a choice of a monochromator ...
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
... ,High Quality, Functionally-Validated, Ion Channel Cell Lines ... having a critical role in nerve and ... function in pain, CNS and the heart. ... investigated in therapeutic areas, such as neuropathic ...
Biology Products: